Germans reject health reform hike

16 July 2006

A majority of Germans - 55% of those polled in a survey for the daily newspaper Die Welt - have rejected the plan to raise the health fund contribution rates 0.5% (Marketletter July 10). The 55% said this was the wrong way to counter the cost explosion in the health service. However, 39% said that they welcomed the coalition government's compromise agreement, although 90% did not believe that fund contribution rates would remain stable until 2013, as is hoped.

A significant majority (79%) said that patients also had responsibility for costs and had to be more aware of them and 73% valued their personal health so highly that they said they were prepared to spend more on preserving it. The survey highlighted a difference of view between the generations; while the over 60s assessed the health service as positive (69% against 27% negative), the 18-24-year-olds returned a generally negative assessment (59% against 37%). The survey also appears to show that the entire health debate over recent months has actually damaged the government, although 25% of those questioned said they remained satisfied.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight